Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463455 | 1.00 | TLR2 (0.50) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL12231705 | 1.00 | TLR2 (0.50) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL16048758 | 0.94 | TLR2 (0.51) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL16048760 | 0.94 | TLR2 (0.51) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL12254867 | 0.93 | TLR2 (0.57) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL14026846 | 0.93 | TLR2 (0.49) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL25845385 | 0.92 | TLR2 (0.54) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL18709106 | 0.91 | TLR2 (0.49) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL23447188 | 0.90 | TLR2 (0.56) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL30684555 | 0.90 | TLR2 (0.58) | TLR2KMT2AMDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638489-A1 | PROTEIN-BASED CONJUGATION CARRIERS | Ablynx N.V. (BE) | 2025-10-29 | — | — | EP | disclosed |
| US-20240415974-A1 | PROTEIN-BASED CONJUGATION CARRIERS | ABLYNX N.V. (BE) | 2024-12-19 | — | — | US | disclosed |
| WO-2024133935-A1 | PROTEIN-BASED CONJUGATION CARRIERS | ABLYNX NV (BE) | 2024-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415974-A1 | PROTEIN-BASED CONJUGATION CARRIERS | HSPBP1, STAMBP, CRYAB | TLR2 2433/4885KMT2A 3949/4885MDM2 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.